RxDoctor Payments Data

Alexa Barron

Family · Utica, NYNPI 1306450168

Payments from drug & device makers

$1,861in general payments, 2019–2025

Across 73 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$630
  • E.r. Squibb & Sons, L.L.C.$367
  • AstraZeneca$279
  • Boehringer Ingelheim$149
  • Irhythm Technologies, Inc.$64
  • Merck$49
  • plus $322 from 14 others

What the payments were for

  • Food & beverage$1,84999%
  • Other$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,861 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$216,614
EntrestoSacubitril/Valsartan56$74,378
Repatha SureclickEvolocumab35$33,478
FarxigaDapagliflozin Propanediol19$19,457
XareltoRivaroxaban15$17,128
Praluent PenAlirocumab24$17,081
Ranolazine ErRanolazine48$7,772
Telmisartan230$7,443
Metoprolol Succinate232$5,290
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid25$3,071
Atorvastatin Calcium223$2,641
Verapamil SrVerapamil Hcl28$2,640
Rosuvastatin Calcium179$2,440
Chlorthalidone84$2,341
Torsemide105$2,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$216,614170 claims
NovartisEntresto$27$74,37856 claims
AstraZenecaFarxiga$279$19,45719 claims
Johnson & JohnsonXarelto$33$17,12815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →